Progressive cardiac dysfunction and fibrosis in the cardiomyopathic hamster and effects of growth hormone and angiotensin-converting enzyme inhibition.

BACKGROUND Growth hormone (GH) improves cardiac function in the rat with myocardial infarction, but its effects in a model of primary dilated cardiomyopathy have not been reported. GH effects were examined at early (4 months) and late (10 months) phases of disease in the cardiomyopathic (CM) hamster, and the combination of GH with chronic ACE inhibition was assessed in late-phase heart failure. METHODS AND RESULTS CM hamsters (CHF 147 line) at 4 months showed severe systolic left ventricular (LV) dysfunction with normal LV filling pressure, and at 10 months there was more severe systolic as well as diastolic dysfunction with increasing myocardial fibrosis. Recombinant human GH alone for 3 weeks at age 4 months increased LV wall thickness and reduced systolic wall stress without altering diastolic wall stress, whereas at 10 months, wall stress and fractional shortening did not improve. The LV dP/dt(max) was enhanced at both ages by GH, which at 4 months reflected increased contractility, but at 10 months was most likely caused by elevation of the LV filling pressure. The increasing degree of fibrosis correlated inversely with LV function but was unaffected by GH. In other CM hamsters, high-dose ACE inhibition alone (quinapril), started at 8 months and continued for 11 weeks, improved LV function and inhibited unfavorable remodeling, but the addition of GH for 3 weeks at age 10 months produced increased wall thickness with little additional functional benefit and increased the LV filling pressure and diastolic wall stress. CONCLUSIONS GH treatment alone improved LV dysfunction at 4 months of age in CM hamsters by increasing contractility and reducing wall stress but had few beneficial effects at 10 months in severe LV failure. After chronic ACE inhibition, addition of GH at 10 months had no additional beneficial effects and further increased LV diastolic pressure. These differing effects of GH may relate to the progressive increase of LV fibrosis in the CM hamster.

[1]  JürgenMeyer,et al.  Recombinant Growth Hormone Therapy in Patients With Ischemic Cardiomyopathy , 1999 .

[2]  J. Ross Growth hormone, cardiomyocyte contractile reserve, and heart failure. , 1999, Circulation.

[3]  T. Voigtländer,et al.  Recombinant growth hormone therapy in patients with ischemic cardiomyopathy : effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity. , 1999, Circulation.

[4]  L. Saccá,et al.  Growth Hormone and the Heart , 1999, Mineral and Electrolyte Metabolism.

[5]  J. Ross,et al.  Angiotensin II blockade followed by growth hormone as adjunctive therapy after experimental myocardial infarction. , 1998, Journal of cardiac failure.

[6]  M. Friedrich,et al.  Randomized, double-blind, placebo-controlled trial of growth hormone in patients with dilated cardiomyopathy , 1998 .

[7]  P. Poole‐Wilson,et al.  Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy , 1998, The Lancet.

[8]  M. Yano,et al.  Growth hormone enhances cardiac performance and sarcoplasmic reticulum Ca2+releasing channels (ryanodine receptors) in cardiomyopathic hamsters , 1998 .

[9]  Y. Murakami,et al.  Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Ross,et al.  Force-frequency effect is a powerful determinant of myocardial contractility in the mouse. , 1997, The American journal of physiology.

[11]  Y. Hayashizaki,et al.  Identification of the Syrian hamster cardiomyopathy gene. , 1997, Human Molecular Genetics.

[12]  J. Ross,et al.  Transthoracic echocardiography in models of cardiac disease in the mouse. , 1996, Circulation.

[13]  J. Ross,et al.  Cardiovascular effects of insulin-like growth factor-1 and growth hormone in chronic left ventricular failure in the rat. , 1996, Circulation.

[14]  E. Bove,et al.  Collagen content in normal, pressure, and pressure-volume overloaded developing human hearts. , 1996, The American journal of cardiology.

[15]  B. Biondi,et al.  A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. , 1996, The New England journal of medicine.

[16]  J. Mayer,et al.  Ten-year institutional experience with palliative surgery for hypoplastic left heart syndrome. Risk factors related to stage I mortality. , 1995, Circulation.

[17]  RenhuiYang,et al.  Growth Hormone Improves Cardiac Performance in Experimental Heart Failure , 1995 .

[18]  R. Ross,et al.  Acquired growth hormone resistance. , 1995, European journal of endocrinology.

[19]  S. Coughlin,et al.  Idiopathic dilated cardiomyopathy. , 1994, The New England journal of medicine.

[20]  V. Fuster,et al.  Idiopathic dilated cardiomyopathy. , 1994, The New England journal of medicine.

[21]  C. Carella,et al.  Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. , 1993, The Journal of clinical endocrinology and metabolism.

[22]  J. Keiser,et al.  Effects of quinapril, a new angiotensin converting enzyme inhibitor, on left ventricular failure and survival in the cardiomyopathic hamster. Hemodynamic, morphological, and biochemical correlates. , 1991, Circulation research.

[23]  E. B. Pedersen,et al.  Expansion of extracellular volume and suppression of atrial natriuretic peptide after growth hormone administration in normal man. , 1991, The Journal of clinical endocrinology and metabolism.

[24]  A. Weissberger,et al.  The antinatriuretic action of biosynthetic human growth hormone in man involves activation of the renin-angiotensin system. , 1990, Metabolism: clinical and experimental.

[25]  B. Sherman,et al.  Variability in the quantitation of circulating growth hormone using commercial immunoassays. , 1989, The Journal of clinical endocrinology and metabolism.

[26]  M. Fishbein,et al.  Cardiac architectural changes with hypertrophy induced by excess growth hormone in rats. , 1988, Laboratory investigation; a journal of technical methods and pathology.

[27]  W. Little,et al.  The Left Ventricular dP/dtmax‐End‐Diastolic Volume Relation in Closed‐Chest Dogs , 1985, Circulation research.

[28]  E. G. Hunter,et al.  Cardiomyopathic hamsters, CHF 146 and CHF 147: a preliminary study. , 1984, Canadian journal of physiology and pharmacology.

[29]  E. Froesch,et al.  Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia. , 1981, The Journal of clinical investigation.

[30]  J. Ross,et al.  Afterload mismatch and preload reserve: a conceptual framework for the analysis of ventricular function. , 1976, Progress in cardiovascular diseases.

[31]  W Grossman,et al.  Wall stress and patterns of hypertrophy in the human left ventricle. , 1975, The Journal of clinical investigation.

[32]  E. Bajusz Hereditary cardiomyopathy: a new disease model. , 1969, American heart journal.